MVA of factors influencing EFS and OS in NK patients receiving induction chemotherapy (n = 76)
| Variable . | P . | HR . | 95% CI . |
|---|---|---|---|
| EFS | |||
| • Two DNMT3A mutations | .038 | 3.192 | 1.068 = 9.542 |
| • Received allo-SCT (in CR1) | .001 | 0.295 | 0-0.595 |
| OS | |||
| • DNMT3AHIGH | .010 | 3.003 | 1.308-6.896 |
| • BM blast % (continuous, per % increase) | .025 | 1.026 | 1.003-1.049 |
| • Two DNMT3A mutations | .020 | 4.816 | 1.284-18.061 |
| Variable . | P . | HR . | 95% CI . |
|---|---|---|---|
| EFS | |||
| • Two DNMT3A mutations | .038 | 3.192 | 1.068 = 9.542 |
| • Received allo-SCT (in CR1) | .001 | 0.295 | 0-0.595 |
| OS | |||
| • DNMT3AHIGH | .010 | 3.003 | 1.308-6.896 |
| • BM blast % (continuous, per % increase) | .025 | 1.026 | 1.003-1.049 |
| • Two DNMT3A mutations | .020 | 4.816 | 1.284-18.061 |
CI, confidence interval; NK, normal karyotype.